Zoetis generated $2387000000 in revenue for Q4 2025, up 3% year over year, with net income of $603000000 and diluted EPS of $1.37. Growth was supported by International operations and continued momentum in companion animal products.

Zoetis delivered $2.4 billion in revenue and $721 million in net income for Q3 2025. Adjusted EPS came in at $1.70, reflecting strong execution and growth in companion animal products and international operations.

Zoetis delivered strong Q2 2025 results with $2.5B in revenue and $718M in net income, driven by an 8% increase in companion animal sales. The company raised its full-year 2025 outlook based on continued disciplined execution and robust performance in the first half.

Zoetis delivered $2.2 billion in revenue and $631 million in net income, with strong performance in companion animal products driving 9% organic growth.

Zoetis reported strong Q4 2024 results with revenue growth of 5% YoY, driven by a 9% operational increase in companion animal products. Net income increased by 11%, and adjusted EPS grew by 13%. The livestock segment declined due to divestitures.

Zoetis reported strong Q3 2024 results, with revenue reaching $2.4 billion, an 11% increase compared to Q3 2023. Net income grew by 14% to $682 million, and adjusted net income increased by 15%. The company has raised its full-year 2024 revenue and adjusted EPS guidance, reflecting confidence in its diverse portfolio and market leadership.

Zoetis reported an 8% increase in revenue to $2.4 billion for the second quarter of 2024. Net income decreased by 7% to $624 million, or $1.37 per diluted share. The company raised its full-year 2024 revenue guidance to $9.100 - $9.250 billion and expects adjusted diluted EPS of $5.78 to $5.88.

Zoetis reported strong first-quarter results for 2024, with revenue reaching $2.2 billion, a 10% increase compared to the previous year. Net income also saw a rise, amounting to $599 million, or $1.31 per diluted share, marking a 9% increase. The company has updated its full-year revenue guidance to $9.050 - $9.200 billion and expects diluted EPS of $5.34 to $5.44 on a reported basis.

Zoetis' Q4 2023 earnings showcased strong performance with revenue reaching $2.2 billion, an 8% increase year-over-year. Net income grew by 14% to $525 million, with adjusted EPS at $1.24. The company's growth was fueled by companion animal products, particularly monoclonal antibody products and dermatology portfolios.

Zoetis reported a 7% increase in revenue, reaching $2.2 billion for Q3 2023. Net income increased by 13% to $596 million, with earnings per diluted share at $1.29. Adjusted net income was $629 million, or $1.36 per diluted share. The company has updated its full-year revenue guidance to $8.475 - $8.550 billion due to foreign exchange rates and narrowed operational growth guidance.

Zoetis reported a revenue of $2.2 billion for the second quarter of 2023, representing a 6% increase compared to the previous year. Net income reached $671 million, or $1.45 per diluted share, a 27% increase. The company is maintaining its full-year guidance for operational revenue growth of 6% to 8% and adjusted net income growth of 7% to 9%.

Zoetis reported a 1% increase in revenue to $2.0 billion for Q1 2023, with a net income of $552 million, a 7% decrease. Adjusted net income was $607 million, a 3% decline. The company maintained its full-year revenue guidance of $8.575 - $8.725 billion and operational revenue growth of 6% to 8%.

Zoetis Q4 2022 earnings report shows a 4% increase in revenue, reaching $2.0 billion, and a net income of $461 million, or $0.99 per diluted share. Adjusted net income was $539 million, or $1.15 per diluted share. The company's operational growth in revenue was 9%, and adjusted net income grew by 27%.

Zoetis reported revenue of $2.0 billion for the third quarter of 2022, a 1% increase compared to the third quarter of 2021. Net income was $529 million, a decrease of 4%. The company lowered its full year 2022 revenue guidance to $8.000 - $8.075 billion.

Zoetis reported a strong second quarter with revenue of $2.1 billion, a 5% increase compared to the previous year. Net income was $529 million, or $1.12 per diluted share, representing a 3% and 5% increase, respectively.

Zoetis reported a strong first quarter in 2022, with revenue reaching $2.0 billion, a 6% increase compared to the previous year. Net income increased by 6% to $595 million, with diluted earnings per share rising by 8% to $1.26. Adjusted net income was $625 million, or $1.32 per diluted share, representing a 4% increase. The company has updated its full-year guidance to reflect the negative impact of foreign exchange rates.

Zoetis reported Q4 2021 revenue of $2.0 billion, a 9% increase compared to Q4 2020. Net income for Q4 2021 was $414 million, a 15% increase. Adjusted net income was $474 million, an 8% increase.

Zoetis reported strong Q3 2021 results with revenue of $2.0 billion, an 11% increase compared to Q3 2020. Net income was $552 million, a 15% increase. Adjusted net income was $597 million, a 14% increase. The company has increased its full year 2021 revenue guidance to $7.700 - $7.750 billion and diluted EPS of $4.23 - $4.29 on a reported basis, or $4.62 - $4.67 on an adjusted basis.

Zoetis reported a strong second quarter with revenue of $1.9 billion, a 26% increase compared to the previous year. Net income increased by 36% to $512 million, or $1.07 per diluted share. The company has raised its full-year guidance for revenue to $7.625 - $7.700 billion and diluted EPS to $4.09 - $4.19 on a reported basis.

Zoetis reported a strong start to 2021 with a 22% increase in revenue to $1.9 billion and a 32% increase in net income to $559 million, or $1.17 per diluted share. The company's adjusted net income increased by 33% to $603 million, or $1.26 per diluted share. Due to this strong performance, Zoetis increased its full year 2021 revenue guidance to $7.500 - $7.625 billion and diluted EPS of $4.08 - $4.19 on a reported basis, or $4.42 - $4.51 on an adjusted basis.

Zoetis reported strong Q4 2020 results, with revenue increasing by 8% to $1.8 billion and net income reaching $359 million. The company's companion animal products, particularly Simparica Trio and key dermatology brands, drove growth in the U.S. International sales also increased, with companion animal products and swine products in China contributing to the positive results. Looking ahead, Zoetis provided full year 2021 revenue guidance of $7.400 - $7.550 Billion, with Diluted EPS of $4.02 - $4.14 on a Reported Basis, or $4.36 - $4.46 on an Adjusted Basis.

Zoetis reported a strong third quarter in 2020, with revenue reaching $1.8 billion, a 13% increase compared to the previous year. Net income also saw an 11% increase, amounting to $479 million, or $1.00 per diluted share. The company's companion animal business was a key driver of growth, and livestock also contributed positively, especially in the U.S. cattle and China's swine markets. Due to the strong performance, Zoetis is increasing its full-year guidance for 2020.

Zoetis reported flat revenue of $1.5 billion for the second quarter of 2020, with a net income of $377 million, or $0.79 per diluted share. Adjusted net income was $427 million, or $0.89 per diluted share. The company raised and narrowed its full year 2020 revenue guidance to $6.300 - $6.475 billion and diluted EPS of $3.14 - $3.32 on a reported basis, or $3.52 - $3.68 on an adjusted basis.

Zoetis reported a revenue of $1.5 billion for Q1 2020, a 5% increase compared to Q1 2019. Net income was $423 million, or $0.88 per diluted share, a 36% increase. Adjusted net income was $455 million, or $0.95 per diluted share, a 7% increase. The company lowered its full year 2020 guidance due to the estimated impact of the COVID-19 outbreak and recessionary conditions.

Zoetis reported a strong fourth quarter and full year in 2019, with revenue reaching $1.7 billion for the quarter, a 7% increase compared to the previous year. Net income for the quarter was $384 million, or $0.80 per diluted share. The company is launching Simparica® Trio in 2020 and is focused on innovation and growth areas.